Drugs to prevent aneurysm

Juan Miguel Redondo Moya

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Spain

Marfan syndrome is a minority disease affecting the cardiovascular system. The main clinical complication of this disease is the high risk of developing a thoracic aortic aneurysm. In this pathology, the blood vessel dilates and can rupture, causing death.

The only current treatment that improves the patient’s life expectancy and quality of life is a surgical intervention to prevent rupture of the aorta. However, there are no drugs that achieve the same effect.

In this sense, the project seeks to find new pharmacological therapies based on the inhibition of proteins whose alteration leads to the formation of the aneurysm. In addition, it seeks to delve into the pathology of Marfan syndrome and improve the diagnosis and prognosis of the disease.

Miguel R. Campanero García, Consejo Superior de Investigaciones Científicas (CSIC), Spain

Nitric Oxide signaling and proteoglycans in Marfan syndrome’s aortopathy: mechanisms and new therapeutic drugs

€500,000